Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients [0.03%]
日本患者的固定剂量瑞戈非尼及其代谢产物M-2和M-5的谷浓度与白蛋白-胆红素分级之间的关联性研究
Kazuma Fujita,Daiki Taguchi,Koji Fukuda et al.
Kazuma Fujita et al.
The aim of the present study was to determine whether the trough plasma concentrations (C0) of regorafenib and its metabolites, the N-oxide metabolite (M-2) and the desmethyl N-oxide metabolite (M-5), in 21 patients receiving regorafenib th...
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors [0.03%]
赛美替尼与派姆单抗联合治疗晚期或转移性实体瘤的1期试验
Maxime Chénard-Poirier,Aaron R Hansen,Martin E Gutierrez et al.
Maxime Chénard-Poirier et al.
MEK inhibitors have immunomodulatory activity and potential for synergistic activity when combined with PD-1 inhibitors. We evaluated selumetinib (inhibitor of MEK1/2) plus pembrolizumab (anti‒PD-1 antibody) in patients with advanced/metas...
Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status [0.03%]
卡马西平对结直肠癌中SMARCA4（BRG1）表达的影响：KRAS突变状态的调节作用
Aaron Shaykevich,Danbee Chae,Isaac Silverman et al.
Aaron Shaykevich et al.
SMARCA4 is a gene traditionally considered a tumor suppressor. Recent research has however found that SMARCA4 likely promotes cancer growth and is a good target for cancer treatment. The drug carbamazepine, an autophagy inducer, was used on...
A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer [0.03%]
AbGn-107（一种新型抗体偶联药物）在晚期胃肠癌患者中进行的多中心Ia期研究
Andrew H Ko,Andrew L Coveler,Benjamin L Schlechter et al.
Andrew H Ko et al.
AbGn-107 is an antibody-drug conjugate directed against AG-7 antigen, a Lewis A-like glycol-epitope expressed in a variety of gastrointestinal (GI) malignancies. Based on promising antitumor activity of AbGn-107 in both in vitro and in vivo...
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages [0.03%]
新型细胞毒性多聚双膦酸盐骨髓dex通过增强成熟破骨细胞的细胞死亡来减少骨吸收，而不影响RANKL刺激的小鼠骨髓巨噬细胞的破骨细胞生成
Petra Henning,Anna Westerlund,Sofia Movérare-Skrtic et al.
Petra Henning et al.
It has previously been demonstrated that the polybisphosphonate osteodex (ODX) inhibits bone resorption in organ-cultured mouse calvarial bone. In this study, we further investigate the effects by ODX on osteoclast differentiation, formatio...
First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab? [0.03%]
驱动基因阴性的恶性胸腔积液的转移性肺腺癌的一线治疗：应该将化疗与免疫检查点抑制剂或贝伐珠单抗联用吗？
Yuanyuan Zhao,Ting Mei,Feifei Na et al.
Yuanyuan Zhao et al.
Patients with metastatic lung adenocarcinoma (MLA) and malignant pleural effusion (MPE) without driver gene mutations have a poor prognosis. None of the standard treatment strategies is recommended for such patients. We retrospectively anal...
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma [0.03%]
一项评估晚期肾细胞癌患者中PY314联合pembrolizumab的安全性、耐受性、药代动力学和药效学的1b期开放标签研究
Kathryn E Beckermann,Amita Patnaik,Ira Winer et al.
Kathryn E Beckermann et al.
Checkpoint inhibition (CPI) is a standard therapeutic approach in metastatic renal cell carcinoma (RCC). However, not all patients respond to CPI, and the immune suppressive characteristics of the RCC tumor microenvironment may contribute t...
Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma [0.03%]
针对LEF1介导的上皮-间充质转化可逆转肝细胞癌中的乐伐替尼耐药性
Xinxiu Li,Hongmeng Su,Wenqing Tang et al.
Xinxiu Li et al.
Acquired resistance is a significant hindrance to clinical application of lenvatinib in unresectable hepatocellular carcinoma (HCC). Further in-depth investigation of resistance mechanisms can help to develop additional therapeutic strategi...
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer [0.03%]
阿帕替尼联合化疗是否联合免疫治疗对比单独化疗作为晚期胃癌一线治疗的安全性和有效性研究
Lele Chang,Xuemei Zhang,Qian Ma et al.
Lele Chang et al.
The specific first-line regimen for advanced gastric cancer (GC) is still controversial. The benefit of apatinib for first-line treatment of advanced GC remains unknown and needs to be further explored. Eighty-two patients with advanced GC ...
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study [0.03%]
PD-1抑制剂联合白蛋白紫杉醇和阿帕替尼作为转移性胃癌二线治疗：一项单中心、单臂、二期研究
Miaomiao Gou,Yong Zhang,Zhikuan Wang et al.
Miaomiao Gou et al.
Background: Immune checkpoint inhibitors have been approved for first- and third-line treatment of advanced gastric cancer. However, pembrolizumab alone in the second line did not improve overall survival compared to chem...